PS1097 

PS1097 is a broad-spectrum antiviral inhibitor with a BVDV RdRp IC₅₀ of 0.64 μM. PS1097 selectively reduces RTN3 protein levels, causes partial RTN3 mRNA reduction, and leaves other endoplasmic reticulum-resident proteins unaffected. PS1097 inhibits replication of Zika virus and multiple viruses that use the endoplasmic reticulum as a replication hub. PS1097 inhibits BVDV RdRp enzymatic activity and exerts activity against Bovine Viral Diarrhea Virus. PS1097 can be used for the research of zika virus infection, usutu virus infection, west nile virus infection, COVID-19, coxsackie b virus 5 infection, chikungunya virus infection, vaccinia virus infection^[1][2][3].

PS1097 (1.7-100 μM; 48 h) potently inhibits ZIKV Brazil/2016/INMI1 replication in Huh-7 cells with an EC₅₀ of 0.69 μM and a high Selectivity Index of 331.7^[1].
PS1097 (100 μM starting serial dilutions; 48 h most assays) exhibits broad-spectrum antiviral activity against multiple RNA and DNA viruses that rely on endoplasmic reticulum remodeling for replication, with EC₅₀ values ranging from 0.1 to 5.51 μM across susceptible virus-cell line pairs, and high Selectivity Indices in most systems^[1].
PS1097 (0.6-6 μM; 48 h) dose-dependently inhibits ZIKV NS5 protein synthesis in Huh-7 and Vero E6 cells, with maximal inhibition observed at 6 μM^[1].
PS1097 (6 μM; 48 h) potently and selectively downregulates reticulon 3 protein levels in Huh-7 cells, with a partial reduction in corresponding reticulon 3 mRNA levels^[1].
PS1097 (1.7-100 μM; 48 h) potently inhibits ZIKVBr replication in Huh-7 cells with an EC₅₀ of 0.69 μM and a high SI of 331.7, indicating strong antiviral activity with low cytotoxicity^[2].
PS1097 (0.6-6 μM; 48 h) dose-dependently inhibits ZIKVBr protein synthesis in Huh-7 and Vero E6 cells, leading to reduced viral yield^[2].
PS1097 (6 μM; 48 h) potently and selectively downregulates RTN3 protein levels in Huh-7 cells, with a partial reduction in RTN3 mRNA, suggesting a post-transcriptional component to the protein depletion^[2].
PS1097 (3-4 days post-viral infection) potently inhibits BVDV-induced cytopathogenicity in MDBK cells with an EC₅₀ of 1.3 μM and shows no significant cytotoxicity up to 100 μM^[3].
PS1097 potently inhibits purified BVDV NS5B∆24 polymerase activity with an IC₅₀ of 0.64 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

313.76

C₁₅H₈ClN₃OS

1822320-58-0

O=C1NC2=C(N=C1C3=CC=CS3)C(Cl)=C4N=CC=CC4=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Plicanti E, et al. A Pyrido-Quinoxaline Derivative That Downregulates Reticulon 3 Protein Exhibits Potent Antiviral Activity Against Zika Virus. J Med Virol. 2025;97(9):e70605.  [Content Brief]

  [2]. Briguglio I, et al. Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. Eur J Med Chem. 2015;105:63-79.  [Content Brief]